Berliner Boersenzeitung - New hope for patients with less common breast cancer

EUR -
AED 4.317194
AFN 81.101956
ALL 97.499245
AMD 451.890977
ANG 2.103509
AOA 1077.834756
ARS 1447.508047
AUD 1.788866
AWG 2.118645
AZN 1.996417
BAM 1.949435
BBD 2.37355
BDT 144.20916
BGN 1.956188
BHD 0.443103
BIF 3455.653573
BMD 1.175392
BND 1.496813
BOB 8.123477
BRL 6.37369
BSD 1.175562
BTN 100.231746
BWP 15.529297
BYN 3.847139
BYR 23037.690484
BZD 2.36139
CAD 1.594414
CDF 3391.006847
CHF 0.935236
CLF 0.028409
CLP 1090.17705
CNY 8.42216
CNH 8.427851
COP 4689.815563
CRC 593.462359
CUC 1.175392
CUP 31.147898
CVE 110.339942
CZK 24.631111
DJF 208.890999
DKK 7.461115
DOP 70.347392
DZD 152.639957
EGP 58.001852
ERN 17.630886
ETB 159.207209
FJD 2.629586
FKP 0.86286
GBP 0.86131
GEL 3.197555
GGP 0.86286
GHS 12.165345
GIP 0.86286
GMD 84.043616
GNF 10174.196361
GTQ 9.03849
GYD 245.946989
HKD 9.226807
HNL 30.771549
HRK 7.535091
HTG 154.356031
HUF 398.769509
IDR 19078.028662
ILS 3.920662
IMP 0.86286
INR 100.396729
IQD 1539.764007
IRR 49513.403353
ISK 142.410553
JEP 0.86286
JMD 187.806815
JOD 0.833353
JPY 170.485955
KES 152.207613
KGS 102.787762
KHR 4726.252344
KMF 491.314092
KPW 1057.884384
KRW 1602.910014
KWD 0.358953
KYD 0.979701
KZT 610.825669
LAK 25335.5827
LBP 105315.156011
LKR 352.678513
LRD 235.665122
LSL 20.651303
LTL 3.470628
LVL 0.710983
LYD 6.323643
MAD 10.550615
MDL 19.796365
MGA 5212.864902
MKD 61.525386
MMK 2467.391102
MNT 4214.11342
MOP 9.504568
MRU 46.659729
MUR 52.704168
MVR 18.100048
MWK 2041.071836
MXN 21.952204
MYR 4.96309
MZN 75.178066
NAD 20.651589
NGN 1803.486634
NIO 43.19542
NOK 11.833304
NPR 160.370394
NZD 1.937753
OMR 0.451943
PAB 1.175562
PEN 4.179677
PGK 4.930788
PHP 66.285103
PKR 333.752413
PLN 4.241947
PYG 9372.399337
QAR 4.279136
RON 5.05901
RSD 117.194818
RUB 92.945398
RWF 1685.512661
SAR 4.408028
SBD 9.799157
SCR 16.554512
SDG 705.821976
SEK 11.267329
SGD 1.499148
SHP 0.923674
SLE 26.387427
SLL 24647.394644
SOS 671.734839
SRD 43.706933
STD 24328.248985
SVC 10.286415
SYP 15282.193175
SZL 20.651192
THB 38.137375
TJS 11.397089
TMT 4.125627
TND 3.393944
TOP 2.752882
TRY 46.813128
TTD 7.964994
TWD 33.982356
TZS 3093.090911
UAH 49.085437
UGX 4217.230841
USD 1.175392
UYU 47.096232
UZS 14815.821182
VES 128.674315
VND 30795.280137
VUV 139.81187
WST 3.05782
XAF 653.822286
XAG 0.031909
XAU 0.000353
XCD 3.176556
XDR 0.812649
XOF 654.071261
XPF 119.331742
YER 284.621858
ZAR 20.587109
ZMK 10579.940853
ZMW 28.360404
ZWL 378.475864
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

New hope for patients with less common breast cancer
New hope for patients with less common breast cancer / Photo: ANNE-CHRISTINE POUJOULAT - AFP/File

New hope for patients with less common breast cancer

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday.

Text size:

Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20 percent of all breast cancer cases.

HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread.

Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years.

"Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP.

The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.

- 'Smart bomb' -

This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney.

"Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much."

Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring.

T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab.

In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects.

A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported.

- 44 percent risk reduction -

At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care.

Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.

Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in.

Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission.

"This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study

(U.Gruber--BBZ)